TOI — Oncology Institute Cashflow Statement
0.000.00%
- $39.01m
- $61.56m
- $324.24m
- 27
- 73
- 18
- 33
Annual cashflow statement for Oncology Institute, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.02 | -14.3 | -10.9 | 0.152 | -83.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.421 | 12 | -9.36 | -45.9 | 38.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3.45 | 0.992 | -14.5 | -20.2 | 2.36 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 3.62 | 0.508 | -32.7 | -61.8 | -36.3 |
Capital Expenditures | -1.2 | -1.19 | -3.05 | -5.53 | -4.57 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | -7.65 | -9.11 | -126 | 67.2 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1.2 | -8.84 | -12.2 | -132 | 62.6 |
Financing Cash Flow Items | — | -0.343 | 141 | -5.93 | -5.85 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.002 | 11.9 | 154 | 92.2 | -6.85 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.41 | 3.55 | 109 | -101 | 19.5 |